JAGX

Jaguar Health, Inc. develops and commercializes plant-based prescription medicines, focusing on addressing unmet medical needs globally. Its primary product is crofelemer, an oral solution aimed at treating rare gastrointestinal disorders, including microvillus inclusion disease and short bowel syndrome with intestinal failure. The company operates through its subsidiaries, Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., leveraging a broad intellectual property portfolio and a diverse botanical library to support its product pipeline.